Articles related to LIPID MANAGEMENT

The 2026 ACC/AHA dyslipidemia guideline reintroduces LDL-C treatment targets, expands risk assessment, and recommends universal Lp(a) screening. New analyses suggest many US adults now exceed recommended cholesterol thresholds, although treatment decisions remain individualized.

A post-thyroidectomy patient’s LDL-C rose above 250 mg/dL during recurrent hypothyroidism and improved after euthyroidism returned. The case highlights medication adherence and secondary-cause review before lipid-therapy escalation.

The FDA approved enlicitide (Lipfendra), the first oral PCSK9 inhibitor for lowering LDL cholesterol in adults with hypercholesterolemia. Approval was based on substantial LDL-C reductions, while cardiovascular outcomes data remain pending.

The FDA approved enlicitide, the first oral PCSK9 inhibitor, after phase 3 studies demonstrated substantial LDL-C reductions in patients requiring additional lipid lowering. Cardiovascular outcomes data remain pending.

The FDA approved olezarsen (Tryngolza), an apoC-III antisense inhibitor, as an adjunct to diet for reducing triglycerides and acute pancreatitis risk in adults with severe hypertriglyceridemia, based on phase 3 data showing an 85% reduction in pancreatitis events compared with placebo.

A 4-week randomized trial in 20 obese men with hypercholesterolemia found that intermittent hypoxic training combined with caloric restriction produced greater reductions in LDL-C, total cholesterol, and triglycerides compared with normoxic training under identical dietary conditions.